Fernando Rivera
Impact in
- Oncology top 0.05%
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Otorhinolaryngology top 0.2%
- Head and Neck Cancer Studies
Papers in
- Oncology 101
- Colorectal Cancer Treatments and Studies 77
- Pancreatic and Hepatic Oncology Research 17
- Cancer Treatment and Pharmacology 15
- Cancer Immunotherapy and Biomarkers 9
-
- Gastric Cancer Management and Outcomes 23
- Co-authors
- Arié Figer (6 shared papers)Eduardo Díaz‐Rubio (20 shared papers)Stephen John Clarke (4 shared papers)Sheryl L. Koski (3 shared papers)Mikhail Lichinitser (3 shared papers)Tsai‐Shen Yang (3 shared papers)Leonard B. Saltz (3 shared papers)Jim Cassidy (3 shared papers)
- Journals
- Annals of Oncology (30 papers)Clinical & Translational Oncology (14 papers)Journal of Clinical Oncology (13 papers)European Journal of Cancer (11 papers)The Oncologist (7 papers)
- Partner nations
- SpainUnited StatesGermany
In The Last Decade
Fernando Rivera
144 papers receiving 19.1k citations
Fernando Rivera's Hit Papers
Peers
Comparison fields: 5 of 128
- Oncology 12.4k
- Otorhinolaryngology 1.7k
- Hepatology 2.2k
- Cancer Research 2.2k
- Pathology and Forensic Medicine 2.6k
Countries citing papers authored by Fernando Rivera
This map shows the geographic impact of Fernando Rivera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fernando Rivera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fernando Rivera more than expected).
Fields of papers citing papers by Fernando Rivera
This network shows the impact of papers produced by Fernando Rivera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fernando Rivera. The network helps show where Fernando Rivera may publish in the future.
Co-authors
The 25 scholars most cited alongside Fernando Rivera, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 147 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer Hit paper breakdown → | 2008 | 2930 |
| 2 | Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study Hit paper breakdown → | 2008 | 2480 |
| 3 | Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer Hit paper breakdown → | 2020 | 2153 |
| 4 | Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer Hit paper breakdown → | 2013 | 1858 |
| 5 | Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study Hit paper breakdown → | 2010 | 1497 |
| 6 | Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer Hit paper breakdown → | 2008 | 724 |
| 7 | OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study Hit paper breakdown → | 2006 | 660 |
| 8 | Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study Hit paper breakdown → | 2022 | 649 |
| 9 | PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer Hit paper breakdown → | 2014 | 528 |
| 10 | Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer Hit paper breakdown → | 2014 | 476 |
| 11 | 2009 | 454 | |
| 12 | 2012 | 422 | |
| 13 | 2011 | 320 | |
| 14 | 2007 | 222 | |
| 15 | 2009 | 213 | |
| 16 | 2012 | 202 | |
| 17 | 2020 | 185 | |
| 18 | 2012 | 170 | |
| 19 | 2006 | 140 | |
| 20 | 2017 | 127 |
About Fernando Rivera
Fernando Rivera is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine, Otorhinolaryngology and Cancer Research, having authored 147 papers that have together received 19.7k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (77 papers), Gastric Cancer Management and Outcomes (23 papers), Pancreatic and Hepatic Oncology Research (17 papers), Cancer Treatment and Pharmacology (15 papers), Genetic factors in colorectal cancer (14 papers), Cancer Genomics and Diagnostics (10 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Head and Neck Cancer Studies (8 papers). The work is most often cited by research in Oncology (12.4k citations), Otorhinolaryngology (1.7k citations), Hepatology (2.2k citations), Cancer Research (2.2k citations) and Pathology and Forensic Medicine (2.6k citations). Fernando Rivera has collaborated with scholars based in Spain, United States and Germany. Frequent co-authors include Arié Figer, Eduardo Díaz‐Rubio, Stephen John Clarke, Sheryl L. Koski, Mikhail Lichinitser, Tsai‐Shen Yang, Leonard B. Saltz, Jim Cassidy, Félix Couture and Werner Scheithauer. Their work appears in journals such as Annals of Oncology, Clinical & Translational Oncology, Journal of Clinical Oncology, European Journal of Cancer and The Oncologist.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.